ArticleCureus2026
Primary Squamous Cell Carcinoma of the Breast: A Case Report and Comprehensive Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary squamous cell carcinoma (SCC) of the breast is one of the rarest forms of metaplastic breast carcinoma. It is typically triple-negative, high-grade, and is associated with aggressive clinical behavior. As it is an extremely rare condition, there is no standardized treatment protocol. We present a case of primary SCC of the breast in a postmenopausal woman who presented with a rapidly growing mass of the breast and an inverted nipple. Histopathology confirmed the diagnosis of SCC of the breast, and immunohistochemistry revealed diffuse p40 positivity. The patient underwent bilateral mastectomy and axillary lymph node dissection, followed by adjuvant chemotherapy and immunotherapy. The patient completed chemotherapy, but immunotherapy had to be stopped due to immune-related endocrine toxicity. This case highlights the diagnostic challenges, treatment modalities, and the emerging role of immunotherapy in this rare subtype of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.